• MGTA-117: An anti-CD117 antibody therapy designed to target hematopoietic stem cells and genetically mutated stem cells for conditioning in blood cancers and genetic diseases.
• CD45-antibody drug conjugate: An investigational therapy targeting hematopoietic stem cells and immune cells for potential use in autoimmune diseases and hematology-oncology transplants.
• MGTA-145: A CXCR2 agonist mobilizing stem cells currently in Phase II clinical trial for use in autologous and allogeneic transplants.
• E478: A small molecule aryl hydrocarbon receptor antagonist being developed for stem cell-based gene therapy and genome editing.

Marino Garcia, President & Chief Executive Officer, Board Member

Marino Garcia has served as President and Chief Executive Officer of Dianthus Therapeutics since November 2021. Prior to joining Dianthus, Mr. Garcia was Senior Vice President, Corporate and Business Development at Zealand Pharma A/S from October 2018 to October 2021. He previously served as Executive Vice President, Chief Strategy Officer at Synergy Pharmaceuticals from 2014 to 2018. Before Synergy, Mr. Garcia was Head of Business Development for Aptalis Pharma, which was acquired by Forest Laboratories (now Allergan, an AbbVie Company) in 2014. He also served as Vice President, US Commercial Operations and Global New Product Development at Aspreva Pharmaceuticals, which was acquired by Vifor Pharma in 2007. Mr. Garcia started his career in various commercial and strategic roles at large, multinational biopharmaceutical companies, including Merck & Co., Pfizer Inc., and Eli Lilly and Co.. He is known as a "dealmaker" CEO, with a background in corporate development evident in the company's capital raises and strategic reverse merger.

Ryan Savitz, Chief Financial Officer & Chief Business Officer, Treasurer

Ryan Savitz is the Chief Financial Officer and Chief Business Officer at Dianthus Therapeutics, Inc. He was appointed CFO in June 2022 at Former Dianthus, becoming CFO of the combined company at the September 11, 2023 reverse merger, and was promoted to Chief Business Officer on February 7, 2024. Prior to Dianthus, he spent 12 years in Citigroup's Healthcare Investment Banking, where he advised on biopharma capital raising and mergers & acquisitions.

Simrat Randhawa, M.D., Executive Vice President, Head of R&D

Dr. Simrat Randhawa brings over 20 years of clinical practice and pharmaceutical industry experience to Dianthus Therapeutics. He most recently served as Senior Vice President of Clinical and Medical Affairs at Aurinia Pharmaceuticals, an autoimmune-focused company. Dr. Randhawa has held several senior commercial and medical leadership roles in the autoimmune and rare disease areas at large pharmaceutical and biotech companies such as Novartis and Biomarin. He has also supported business development opportunities and integration needs in the healthcare sector while at McKinsey.

Ronny Hashmonay, M.D., Chief Development and Medical Affairs Officer

Dr. Ronny Hashmonay has over 20 years of international experience in the healthcare and pharmaceutical industries. He most recently served as Global Head of Business Transformation for Novartis. In his prior role as Chief Digital Officer at Novartis United States, he spearheaded digital transformation and strategic corporate health tech partnerships. As a member of the Novartis U.S. Executive Committee, Dr. Hashmonay led multiple teams as Head of Business Innovation, Head of Business Development and Licensing, and Head of Launch Excellence.

Edward Carr, Chief Accounting Officer

Edward Carr serves as the Chief Accounting Officer at Dianthus Therapeutics, Inc..

Key Risks to Dianthus Therapeutics (DNTH)

1. Clinical Trial and Regulatory Risk: Dianthus Therapeutics is a clinical-stage biotechnology company, and the success of its business hinges on the successful completion of its clinical trials and subsequent regulatory approvals for its drug candidates. There is no assurance that ongoing or future clinical trials, such as Part B of the Phase 3 CAPTIVATE study for claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), will achieve positive outcomes or meet endpoints in a statistically significant manner, which could prevent the company from filing for or receiving regulatory approval (e.g., Biologics License Application with the FDA). Any safety signals related to its complement system-targeting drugs could also lead to regulatory delays or warnings.
2. Commercialization and Market Competition Risk: Dianthus Therapeutics currently lacks a commercial infrastructure. Building this infrastructure or securing a suitable partner to market and distribute its products, if approved, is a high-stakes endeavor. The company also operates in a highly competitive industry, with established players and other companies developing similar therapies. The entry of more drugs into the markets for conditions like CIDP and generalized Myasthenia Gravis (gMG) could lead to competitive pricing pressures and impact long-term margins. Competitors with greater financial resources and established market presence could hinder Dianthus's market penetration.
3. Financial Vulnerability: As a clinical-stage company, Dianthus Therapeutics has not yet commercialized any products and continues to incur significant losses. While the company has a substantial cash runway, its long-term financial health is dependent on its ability to secure additional capital, manage expenses effectively, and ultimately achieve commercial success with its product candidates. Without a stable revenue stream from commercialized products, the company remains financially vulnerable, and its future success relies on the commercial viability of its pipeline.

Dianthus Therapeutics (DNTH), a clinical-stage biotechnology company, anticipates its future revenue growth over the next 2-3 years to be primarily driven by the successful advancement and potential commercialization of its pipeline of novel antibody complement therapeutics for severe autoimmune and inflammatory diseases. As a company with a trailing 12-month revenue of approximately $2.04 million as of December 31, 2025, its revenue generation is currently limited, typical for a biotechnology company at its stage.

The key drivers for Dianthus Therapeutics' future revenue growth are:

1. Commercialization of Claseprubart (DNTH103) for Generalized Myasthenia Gravis (gMG): Dianthus' lead candidate, claseprubart, a C1s antibody, is being developed for gMG. Positive Phase 2 data was reported in September 2025, and the company plans to initiate a Phase 3 trial in mid-2026, with top-line data expected in the second half of 2028. Successful completion of this pivotal trial and subsequent market approval and launch would represent a significant revenue opportunity in the multibillion-dollar gMG market.
2. Commercialization of Claseprubart (DNTH103) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The company's Phase 3 CAPTIVATE trial for claseprubart in CIDP achieved its early responder target in March 2026, suggesting a strong path toward a single pivotal Biologics License Application (BLA) strategy. Guidance for Part B top-line data is anticipated by year-end 2026. The CIDP market is also identified as a large and growing multibillion-dollar opportunity.
3. Expansion of Claseprubart (DNTH103) into Additional Indications, specifically Multifocal Motor Neuropathy (MMN): Dianthus operates on a "pipeline-in-a-product" model, aiming to leverage claseprubart across multiple indications. Beyond gMG and CIDP, the Phase 2 MoMeNtum trial for claseprubart in MMN is ongoing, with top-line results expected in the second half of 2026. Positive results and eventual commercialization in MMN would further broaden the market reach and revenue potential of claseprubart.
4. Advancement and Potential Commercialization of DNTH212: Dianthus is also developing DNTH212, an investigational bifunctional fusion protein for other autoimmune diseases, including systemic lupus erythematosus. A Phase 1 study in China is underway, with top-line results in healthy volunteers expected in the second half of 2026. The successful clinical development and eventual market entry of DNTH212 would diversify the company's product portfolio and open new revenue streams.

Share Issuance

• Dianthus Therapeutics closed an upsized underwritten public offering in March 2026, raising approximately $719 million in aggregate gross proceeds by selling 8,470,989 common shares and 402,468 pre-funded warrants.
• In September 2025, the company completed an upsized $288 million underwritten public offering.
• Dianthus Therapeutics announced a private investment in public equity (PIPE) financing in January 2024, expected to result in gross proceeds of approximately $230 million.

Inbound Investments

• In September 2023, Dianthus Therapeutics completed a reverse merger with Magenta Therapeutics, providing a cash infusion of $180 million and a Nasdaq listing.
• The company emerged from stealth in May 2022 with a $100 million Series A financing, backed by investors such as 5AM Ventures and Fidelity.
• In January 2024, Dianthus received approximately $230 million in gross proceeds from a PIPE financing with participation from new and existing investors, including Bain Capital Life Sciences and RA Capital Management.

Outbound Investments

• In October 2025, Dianthus Therapeutics acquired an exclusive global license for DNTH212 from Nanjing Leads Biolabs, involving an upfront payment of $30 million and potential milestone payments up to $1 billion.

Capital Expenditures

• Research and development (R&D) expenses for the year ended December 31, 2025, were $145.6 million, an increase from $83.1 million in 2024.
• The increase in R&D expenses in 2025 was primarily driven by higher clinical costs, upfront and clinical development milestones for DNTH212, and increased headcount to support Phase 2 and Phase 3 development.
• As of December 31, 2025, Dianthus reported $514.4 million in cash, cash equivalents, and investments, projected to fund operations into 2028, covering clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes.